Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Electra Therapeutics Secures $183M for Rare Disease Trial, Signaling Positive Market Shift

Electra Therapeutics Secures $183M for Rare Disease Trial, Signaling Positive Market Shift

In a significant development for the pharmaceutical industry, Electra Therapeutics has successfully raised $183 million in a Series C financing round, marking a substantial increase from its previous $84 million fundraise in 2022. This oversubscribed round, co-led by Nextech and EQT Life Sciences, with participation from notable investors including Sanofi and Mubadala Capital, reflects growing investor confidence in innovative biotech companies despite challenging market conditions.

NoahAI News10/22/2025
Regeneron Settles Eylea Patent Dispute with Celltrion, Paving Way for Biosimilar Launch

Regeneron Settles Eylea Patent Dispute with Celltrion, Paving Way for Biosimilar Launch

Regeneron Pharmaceuticals has reached a settlement agreement with South Korean drugmaker Celltrion in their ongoing patent dispute over the blockbuster eye drug Eylea (aflibercept). This development marks a significant shift in the competitive landscape for aflibercept biosimilars in the United States.

NoahAI News10/22/2025
British Biotech Elevara Medicines Emerges with $70M Series A and Promising Rheumatoid Arthritis Asset

British Biotech Elevara Medicines Emerges with $70M Series A and Promising Rheumatoid Arthritis Asset

Elevara Medicines, a newly formed British biotech company, has burst onto the pharmaceutical scene with a substantial $70 million series A funding round and a phase 2-ready asset targeting rheumatoid arthritis (RA). The London-based firm, founded by Weatherden and initially backed by Monograph Capital, is poised to make waves in the treatment of chronic inflammatory conditions.

NoahAI News10/22/2025
FDA Platform Technology Designation: Krystal Biotech Leads the Way After Sarepta Setback

FDA Platform Technology Designation: Krystal Biotech Leads the Way After Sarepta Setback

In a significant development for the pharmaceutical industry, Krystal Biotech has become the second company—and currently the only active recipient—to receive the FDA's Platform Technology Designation. This designation, aimed at accelerating approvals for therapeutics using similar technologies, was awarded to Krystal's modified herpes simplex virus (HSV) vector used in gene therapies.

NoahAI News10/21/2025
Exelixis' Zanzalintinib Shows Promise in Late-Stage Colorectal Cancer Trial

Exelixis' Zanzalintinib Shows Promise in Late-Stage Colorectal Cancer Trial

Exelixis, a prominent player in the pharmaceutical industry, has reported significant progress in its Phase III STELLAR-303 study, evaluating the efficacy of zanzalintinib in combination with Roche's Tecentriq for the treatment of metastatic colorectal cancer (mCRC). The results, presented at the 2025 European Society for Medical Oncology (ESMO) meeting and simultaneously published in The Lancet, demonstrate a notable improvement in overall survival rates, potentially setting a new standard for third-line treatment in mCRC.

NoahAI News10/21/2025
Summit Therapeutics Pursues FDA Application for Ivonescimab Despite Mixed Clinical Results

Summit Therapeutics Pursues FDA Application for Ivonescimab Despite Mixed Clinical Results

Summit Therapeutics is moving forward with plans to submit a regulatory application for ivonescimab, its PD-1/VEGF inhibitor antibody, to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. This decision comes despite the drug's failure to demonstrate a significant overall survival benefit in certain non-small cell lung cancer (NSCLC) patients during its Phase III HARMONi study.

NoahAI News10/21/2025
Private Equity Firm Curewell Capital Invests in Wilmington PharmaTech to Boost US API Production

Private Equity Firm Curewell Capital Invests in Wilmington PharmaTech to Boost US API Production

Curewell Capital, a private equity firm focused on healthcare, has made a significant majority investment in Wilmington PharmaTech (WPT), a specialty contract development and manufacturing organization (CDMO). The move aims to address the gap in U.S. active pharmaceutical ingredient (API) production capacity and capabilities.

NoahAI News10/21/2025
Galapagos to Wind Down Cell Therapy Unit, Impacting 365 Jobs and 5 Facilities

Galapagos to Wind Down Cell Therapy Unit, Impacting 365 Jobs and 5 Facilities

Belgian biotech company Galapagos has announced plans to wind down its cell therapy business, marking a dramatic shift in strategy that will affect hundreds of employees across multiple countries. The decision comes after a six-month period of strategic review and unsuccessful attempts to divest the unit.

NoahAI News10/21/2025
ACG Invests $200M in First US Empty-Capsule Facility, Expanding Global Footprint

ACG Invests $200M in First US Empty-Capsule Facility, Expanding Global Footprint

ACG, a leading supplier and service provider for solid dose drug manufacturers, has announced a significant investment of $200 million to establish its first empty-capsule production facility in the United States. This move marks a major expansion of the India-based company's global operations and strengthens its presence in the North American market.

NoahAI News10/21/2025
Elevance Health Reports Strong Q3 2025 Results, Reaffirms Full-Year Outlook

Elevance Health Reports Strong Q3 2025 Results, Reaffirms Full-Year Outlook

Elevance Health, a major player in the health insurance industry, has reported robust financial results for the third quarter of 2025, surpassing Wall Street expectations and setting a positive tone for the insurance sector's earnings season.Elevance Health posted a profit of $1.2 billion for the third quarter, marking a significant 17% increase from the $1 billion reported in Q3 2024. The company's revenues also saw substantial growth, reaching $50.7 billion, up 12.4% from $45.1 billion in the prior-year quarter.

NoahAI News10/21/2025
Quest Diagnostics and Danaher Report Strong Q3 Sales Amid Potential Tariff Concerns

Quest Diagnostics and Danaher Report Strong Q3 Sales Amid Potential Tariff Concerns

Quest Diagnostics and Danaher, two major players in the medical technology and diagnostics sector, have reported robust third-quarter sales growth for 2025, showcasing resilience in the face of potential industry headwinds. This positive financial performance comes as the pharmaceutical and medical device industries navigate an evolving regulatory landscape, including a recent national security investigation into medical equipment imports.

NoahAI News10/21/2025
Pharmaceutical Industry Confronts Challenges in Personalized mRNA Cancer Vaccine Production

Pharmaceutical Industry Confronts Challenges in Personalized mRNA Cancer Vaccine Production

In a significant shift from mass-produced COVID-19 vaccines, pharmaceutical companies are now grappling with the complexities of manufacturing individualized mRNA cancer vaccines. This emerging field presents unique challenges in production efficiency and timely delivery, as industry leaders like Moderna and BioNTech pioneer new approaches to personalized medicine.

NoahAI News10/21/2025
«1...303132...67»